MX2016006583A - Tratamiento de hipercolesterolemia familiar homocigotica. - Google Patents
Tratamiento de hipercolesterolemia familiar homocigotica.Info
- Publication number
- MX2016006583A MX2016006583A MX2016006583A MX2016006583A MX2016006583A MX 2016006583 A MX2016006583 A MX 2016006583A MX 2016006583 A MX2016006583 A MX 2016006583A MX 2016006583 A MX2016006583 A MX 2016006583A MX 2016006583 A MX2016006583 A MX 2016006583A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- homocigotic
- inhibitor
- family hypercholesterolemia
- hypercholesterolemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361906837P | 2013-11-20 | 2013-11-20 | |
| US201461942438P | 2014-02-20 | 2014-02-20 | |
| US201461942941P | 2014-02-21 | 2014-02-21 | |
| US201461974785P | 2014-04-03 | 2014-04-03 | |
| US201461974725P | 2014-04-03 | 2014-04-03 | |
| US201461974816P | 2014-04-03 | 2014-04-03 | |
| PCT/US2014/065742 WO2015077154A1 (en) | 2013-11-20 | 2014-11-14 | Treatment of homozygous familial hypercholesterolemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016006583A true MX2016006583A (es) | 2016-09-06 |
Family
ID=52014370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006583A MX2016006583A (es) | 2013-11-20 | 2014-11-14 | Tratamiento de hipercolesterolemia familiar homocigotica. |
Country Status (14)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| PT2929031T (pt) | 2012-12-05 | 2018-01-19 | Alnylam Pharmaceuticals Inc | Composições de irna de pcsk9 e métodos de seu uso |
| US9624172B2 (en) | 2014-02-17 | 2017-04-18 | Hetero Research Foundation | Polymorphs of lomitapide and its salts |
| CN106102734B (zh) | 2014-03-20 | 2019-05-14 | 西玛贝医药公司 | 肝内胆汁淤积性疾病的治疗 |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| PL3129018T3 (pl) | 2014-04-11 | 2020-05-18 | Cymabay Therapeutics, Inc. | Leczenie NAFLD i NASH |
| BR102015025502B1 (pt) * | 2015-04-30 | 2022-06-21 | Aegerion Pharmaceuticals, Inc | Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição |
| KR102793532B1 (ko) * | 2015-08-25 | 2025-04-14 | 알닐람 파마슈티칼스 인코포레이티드 | 전구단백질 컨버타제 서브틸리신 켁신 (pcsk9) 유전자-관련 장애를 치료하기 위한 방법 및 조성물 |
| CN105481758A (zh) * | 2016-01-13 | 2016-04-13 | 天津药物研究院有限公司 | 一种洛美他派晶型ⅰ及其制备方法和用途 |
| JP7541810B2 (ja) | 2016-03-03 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| LT3448426T (lt) * | 2016-04-28 | 2025-07-10 | Regeneron Pharmaceuticals, Inc. | Pacientų, sergančių šeimine hipercholesterolemija, gydymo būdai |
| WO2017200715A1 (en) * | 2016-05-19 | 2017-11-23 | Cymabay Therapeutics, Inc. | Treatment of severe hyperlipidemia |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| WO2019101151A1 (zh) * | 2017-11-23 | 2019-05-31 | 浙江海正药业股份有限公司 | 一种海泽麦布和HMG-CoA还原酶抑制剂的药物组合物 |
| CN113710808A (zh) * | 2018-12-20 | 2021-11-26 | 宾夕法尼亚州大学信托人 | 用于治疗家族性高胆固醇血症的基因疗法 |
| US11248001B2 (en) | 2019-01-18 | 2022-02-15 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| US20210145774A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of alcoholic liver disease |
| US20210145775A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of intestinal barrier dysfunction and associated diseases |
| CA3186856A1 (en) * | 2020-07-29 | 2022-02-03 | Ruth NALLEN | Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US7301050B2 (en) | 2003-09-19 | 2007-11-27 | Janssen Pharmaceutical N.V. | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| KR20060129082A (ko) | 2004-03-05 | 2006-12-14 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과연관된 질환 또는 질병의 치료 방법 |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| ES2712052T3 (es) | 2008-10-17 | 2019-05-09 | Cymabay Therapeutics Inc | Métodos para reducir partículas de LDL pequeñas y densas |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
-
2014
- 2014-11-14 AU AU2014353246A patent/AU2014353246A1/en not_active Abandoned
- 2014-11-14 US US14/541,835 patent/US20150139987A1/en not_active Abandoned
- 2014-11-14 WO PCT/US2014/065742 patent/WO2015077154A1/en not_active Ceased
- 2014-11-14 CA CA2930069A patent/CA2930069A1/en not_active Abandoned
- 2014-11-14 HK HK16112450.0A patent/HK1224186A1/zh unknown
- 2014-11-14 MX MX2016006583A patent/MX2016006583A/es unknown
- 2014-11-14 EA EA201691039A patent/EA201691039A1/ru unknown
- 2014-11-14 JP JP2016532631A patent/JP2017505285A/ja not_active Withdrawn
- 2014-11-14 KR KR1020167016225A patent/KR20160079124A/ko not_active Withdrawn
- 2014-11-14 EP EP14809184.6A patent/EP3071198A1/en not_active Withdrawn
- 2014-11-14 CN CN201480063803.XA patent/CN105764498A/zh active Pending
-
2016
- 2016-05-12 PH PH12016500886A patent/PH12016500886A1/en unknown
- 2016-05-19 IL IL245748A patent/IL245748A0/en unknown
- 2016-05-20 CL CL2016001215A patent/CL2016001215A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL245748A0 (en) | 2016-07-31 |
| CL2016001215A1 (es) | 2016-12-09 |
| EP3071198A1 (en) | 2016-09-28 |
| EA201691039A1 (ru) | 2016-11-30 |
| CN105764498A (zh) | 2016-07-13 |
| WO2015077154A1 (en) | 2015-05-28 |
| CA2930069A1 (en) | 2015-05-28 |
| PH12016500886A1 (en) | 2016-06-20 |
| JP2017505285A (ja) | 2017-02-16 |
| HK1224186A1 (zh) | 2017-08-18 |
| AU2014353246A1 (en) | 2016-06-16 |
| US20150139987A1 (en) | 2015-05-21 |
| KR20160079124A (ko) | 2016-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016006583A (es) | Tratamiento de hipercolesterolemia familiar homocigotica. | |
| CL2017000705A1 (es) | Nuevos compuestos | |
| IL282535A (en) | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors | |
| CR20150418A (es) | Compuestos de tetrahidropirrolotiazina | |
| UY36315A (es) | COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6. | |
| JO3392B1 (ar) | مركبات عطرية حلقية غير متجانسة كمركبات مضادة للالتهاب | |
| BR112015000160A2 (pt) | fabricação de ácido 2-(5-bromo-4-(4-ciclopropil hidronaftalen-1-il)-4h-1,2,4-triazol-3-il-tio) acético | |
| EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
| CL2016001458A1 (es) | Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo. | |
| AR098274A1 (es) | Inhibidor de grelina o-acil transferasa | |
| CY1122264T1 (el) | Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων | |
| CL2015002309A1 (es) | Proceso de fabricacion de vortioxetina. | |
| CL2016003290A1 (es) | Tratamiento de hipertrigliceridemia severa. | |
| EA201690911A1 (ru) | Соединения диметилбензойной кислоты | |
| EA201390616A1 (ru) | ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2 | |
| EA201591915A1 (ru) | Соединения феноксиэтил дигидро-1h-изохинолина | |
| MX376785B (es) | Surtidor operado por bateria. | |
| EA201790191A1 (ru) | Новые сульфониламинобензамидные соединения | |
| EP3314851A4 (en) | SINGLE SOLUTION FOR USER CONTROL | |
| PE20171259A1 (es) | Compuestos | |
| EA201690593A1 (ru) | Новые соединения мочевины | |
| DOP2017000016A (es) | Nueva sal de disoproxilo de tenofovir | |
| AR119050A2 (es) | Compuestos del ácido 3,6-diclorosalicílico y procesos de síntesis relacionados | |
| BR112013025399A2 (pt) | máquina para o vazamento de barris de forma automática e higiênica | |
| RU2013110799A (ru) | Средство для профилактики и лечения диабета |